NYSEAMERICAN:NNVC NanoViricides - NNVC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.20 -0.04 (-3.23%) (As of 03/28/2023 04:33 PM ET) Add Compare Share Share Today's Range$1.20▼$1.2950-Day Range N/A52-Week Range$1.04▼$3.88Volume18,268 shsAverage Volume22,976 shsMarket Capitalization$13.93 millionP/E RatioN/ADividend YieldN/APrice Target$5.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NanoViricides MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside337.5% Upside$5.25 Price TargetShort InterestBearish1.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.65 out of 5 stars 3.5 Analyst's Opinion Consensus RatingNanoViricides has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.25, NanoViricides has a forecasted upside of 337.5% from its current price of $1.20.Amount of Analyst CoverageNanoViricides has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.65% of the float of NanoViricides has been sold short.Short Interest Ratio / Days to CoverNanoViricides has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in NanoViricides has recently increased by 103.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNanoViricides does not currently pay a dividend.Dividend GrowthNanoViricides does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NNVC. Previous Next 1.1 News and Social Media Coverage News SentimentNanoViricides has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for NanoViricides this week, compared to 2 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NanoViricides insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of NanoViricides is held by insiders.Percentage Held by InstitutionsOnly 9.62% of the stock of NanoViricides is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of NanoViricides is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NanoViricides is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNanoViricides has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NanoViricides (NYSEAMERICAN:NNVC) StockNanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.Read More Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Email Address NNVC Stock News HeadlinesJanuary 4, 2023 | finance.yahoo.comNanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PTDecember 25, 2022 | finance.yahoo.comNanoViricides, Inc. (NNVC) Stock Historical Prices & Data - Yahoo FinanceMarch 28, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. December 5, 2022 | finance.yahoo.comNanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ETOctober 14, 2022 | finance.yahoo.comNanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND StageOctober 1, 2022 | money.usnews.comNanoViricides IncSeptember 23, 2022 | benzinga.comKoch Modular Process Systems to Discuss Optimal Mixing in Agitated Extraction Columns at ISEC 2022 - BenzingaSeptember 23, 2022 | benzinga.com18-year-old Aashir Khan becomes Head of Product at one of the biggest digital platforms in Brazil - BenzingaMarch 28, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.September 23, 2022 | benzinga.comWhat 5 Analyst Ratings Have To Say About Summit Materials - Summit Materials (NYSE:SUM) - BenzingaSeptember 22, 2022 | benzinga.comXDuce Inc. expands its Global Footprint to the UK - BenzingaSeptember 22, 2022 | benzinga.comFrost & Sullivan Explores the Growing Impact of the Digital Front Door on Healthcare - BenzingaSeptember 22, 2022 | benzinga.comBroken Record? JPMorgan CEO Continues Rant On Bitcoin, Calls It A 'Ponzi Scheme' - JPMorgan Chase (NYSE:J - BenzingaSeptember 22, 2022 | benzinga.comBetter Therapeutics Seeks FDA Approval For First Digital Therapeutic For Type 2 Diabetes - Better Therap - BenzingaSeptember 22, 2022 | benzinga.comCryptocurrency Lido Staked Ether Falls More Than 5% In 24 hours - (STETH/USD) - BenzingaSeptember 22, 2022 | benzinga.comGlobal Healthcare Analytical Testing Services Market Report 2022: Growing Demand for Biosimilars Driving - BenzingaSeptember 22, 2022 | benzinga.comMeet the 50 German Leaders transforming our world - BenzingaSeptember 22, 2022 | benzinga.comTilray's Medical Cannabis Oral Solution Approved For Pharmaceutical Distribution In Italy - Tilray (NASDA - BenzingaSeptember 22, 2022 | benzinga.comAutomotive Fuse Market worth $28.4 billion by 2027 - Exclusive Report by MarketsandMarkets™ - BenzingaSeptember 22, 2022 | benzinga.comMedicenna Announces Results of Annual Meeting of Shareholders - Medicenna Therapeutics (NASDAQ:MDNA) - BenzingaSeptember 22, 2022 | benzinga.com/R E P E A T -- MEDIA ADVISORY - Centraide 2022 Campaign Launch: Helping households and organizations cop - BenzingaSeptember 22, 2022 | benzinga.comThe M&A Class Action Firm Announces an Investigation of Southern Missouri Bancorp. - SMBC - Southern Miss - BenzingaSeptember 22, 2022 | benzinga.comMedical Source Offers Industry Leading Direct-To-Consumer Health Supplies - BenzingaSeptember 21, 2022 | benzinga.comAlibaba Stock Is Falling Today: What's Going On? - Alibaba Group Holding (NYSE:BABA) - BenzingaSeptember 21, 2022 | benzinga.comRa Medical shares are trading higher after the company announced results of its Special Meeting of stockh - BenzingaSeptember 21, 2022 | benzinga.comStrategic Storage Trust VI, Inc. Acquires Storage Facility in The Villages, Florida Market - BenzingaSeptember 21, 2022 | benzinga.com$1000 Invested In This Stock 15 Years Ago Would Be Worth $3,600 Today - Lennar (NYSE:LEN) - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Email Address NNVC Company Calendar Last Earnings2/14/2023Today3/28/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:NNVC Previous SymbolNYSEMKT:NNVC CUSIPN/A CIK1379006 Webwww.nanoviricides.com Phone(203) 937-6137Fax203-859-5095Employees17Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.25 High Stock Price Forecast$5.25 Low Stock Price Forecast$5.25 Forecasted Upside/Downside+318.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,110,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.48% Return on Assets-28.98% Debt Debt-to-Equity RatioN/A Current Ratio25.39 Quick Ratio25.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book0.63Miscellaneous Outstanding Shares11,610,000Free Float11,099,000Market Cap$14.58 million OptionableOptionable Beta0.93 Key ExecutivesAnil R. DiwanExecutive Chairman, President & CEOMeeta R. VyasChief Financial & Accounting OfficerRandall W. BartonChief Scientific OfficerJayant TatakeVice President-Research & DevelopmentKey CompetitorsLexaria BioscienceNASDAQ:LEXXCNS PharmaceuticalsNASDAQ:CNSPCellectar BiosciencesNASDAQ:CLRBHumanigenNASDAQ:HGENCocrystal PharmaNASDAQ:COCPView All CompetitorsInstitutional OwnershipMillennium Management LLCBought 25,012 shares on 2/15/2023Ownership: 0.580%Susquehanna International Group LLPBought 28,000 shares on 2/14/2023Ownership: 0.000%Group One Trading L.P.Sold 2,200 shares on 2/9/2023Ownership: 0.000%Simplex Trading LLCSold 1,300 shares on 2/2/2023Ownership: 0.000%View All Institutional Transactions NNVC Stock - Frequently Asked Questions Should I buy or sell NanoViricides stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoViricides in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NNVC shares. View NNVC analyst ratings or view top-rated stocks. What is NanoViricides' stock price forecast for 2023? 1 Wall Street research analysts have issued 12 month target prices for NanoViricides' stock. Their NNVC share price forecasts range from $5.25 to $5.25. On average, they predict the company's share price to reach $5.25 in the next year. This suggests a possible upside of 318.0% from the stock's current price. View analysts price targets for NNVC or view top-rated stocks among Wall Street analysts. Are investors shorting NanoViricides? NanoViricides saw a increase in short interest in March. As of March 15th, there was short interest totaling 183,800 shares, an increase of 103.5% from the February 28th total of 90,300 shares. Based on an average daily volume of 28,500 shares, the days-to-cover ratio is currently 6.4 days. Approximately 1.7% of the company's shares are sold short. View NanoViricides' Short Interest. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSEAMERICAN:NNVC) announced its quarterly earnings results on Tuesday, February, 14th. The company reported ($0.15) EPS for the quarter. When did NanoViricides' stock split? NanoViricides's stock reverse split on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of NanoViricides own? Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Inovio Pharmaceuticals (INO), Micron Technology (MU), Gilead Sciences (GILD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), iBio (IBIO) and Moderna (MRNA). What is NanoViricides' stock symbol? NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC." Who are NanoViricides' major shareholders? NanoViricides' stock is owned by many different institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.58%), Susquehanna International Group LLP (0.00%), Simplex Trading LLC (0.00%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of NanoViricides? Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NanoViricides' stock price today? One share of NNVC stock can currently be purchased for approximately $1.26. How much money does NanoViricides make? NanoViricides (NYSEAMERICAN:NNVC) has a market capitalization of $14.58 million. The company earns $-8,110,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. How can I contact NanoViricides? NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The official website for the company is www.nanoviricides.com. The company can be reached via phone at (203) 937-6137, via email at info@nanoviricides.com, or via fax at 203-859-5095. This page (NYSEAMERICAN:NNVC) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.